Fulgent Genetics, Inc.

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and globally. Its clinical diagnostic solutions include molecular diagnostic testing, genetic testing, and anatomic pathology laboratory tests such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology. The company also offers oncology tests and sequencer services related to hereditary cancer, reproductive health, and diseases. Its therapeutic development solutions focus on developing drug candidates for treating cancers using a nanoencapsulation and targeted therapy platform. Additionally, Fulgent operates the Picture Genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems to help customers identify health markers in their personal DNA.

Fulgent Genetics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol FLGT. The company trades in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange.

Fulgent Genetics operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This means the company is involved in providing diagnostic testing services and research solutions, including molecular and genetic testing, as well as therapeutic development for cancer treatments.

Fulgent Genetics is headquartered in El Monte, California, United States. The company serves a broad range of customers including insurance companies, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Its services are provided both in the United States and globally.

Fulgent Genetics generates revenue through its clinical diagnostic and therapeutic development solutions. The clinical diagnostic segment offers molecular diagnostic testing, genetic testing, and anatomic pathology services, which are billed to insurance companies, hospitals, medical institutions, and other clients. The therapeutic development segment focuses on developing drug candidates for cancers using a nanoencapsulation and targeted therapy platform, potentially generating revenue through partnerships, licensing, or future product sales. Additionally, the company's Picture Genetics platform provides tools for identifying health markers in personal DNA, which may be offered as a service to customers.